Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-hVEGF siRNA + SilenceMag
- Development stage
- Preclinical
- Lead developer
- OZ Biosciences
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
131I-hVEGF siRNA + SilenceMag is a combination drug comprised of human Vascular Endothelial Growth Factor small interfering RNA (hVEGF siRNA) labeled with radioactive iodine-131 (^131I^) for targeted gene silencing, delivered using SilenceMag, a proprietary magnetic nanoparticle reagent. SilenceMag uses Magnetofection™ technology, which employs magnetic force to concentrate the siRNA delivery at specific tissue sites under the guidance of an external magnetic field (EMF). In preclinical models, this enables simultaneous anti-tumor effects via VEGF gene knockdown (inhibiting angiogenesis) and radioisotope therapy, while also facilitating diagnostic imaging through radiolabel tracking. This approach has shown antitumoral and angiostatic activities, especially for hepatocellular carcinoma (HCC), by enabling high local concentration of siRNA in tumors and real-time imaging/biodistribution assessment[6].
- Other names
- 131I-labeled hVEGF siRNA/SilenceMag
02
Targets
Beyond the preview
Go deeper on 131I-hVEGF siRNA + SilenceMag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 131I-hVEGF siRNA + SilenceMag.